Measuring the Effect of Local Control From Radiotherapy in Patients With Pancreatic Adenocarcinoma-Reference-Cited by-同舟云学术

Measuring the Effect of Local Control From Radiotherapy in Patients With Pancreatic Adenocarcinoma

Published:2022-03-01 Issue:3 Volume:8 Page:337
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sanford Nina N.¹,Yeap Beow Y.²,Hong Theodore S.³

Affiliation:

1. Department of Radiation Oncology, University of Texas Southwestern, Dallas

2. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston

3. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2788574/jamaoncology_sanford_2022_vp_210026_1647458316.18309.pdf

Reference9 articles.

1. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.;Katz;J Clin Oncol

2. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.;Ghaneh;J Clin Oncol,2020

3. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC Trial.;Versteijne;J Clin Oncol,2020

4. Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial.;Van Eijck;J Clin Oncol

5. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.;Janssen;BMC Cancer,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma − Heading towards a promising change in treatment paradigm;Cancer Treatment Reviews;2024-06

2. The impact of local control on widespread progression and survival in oligometastasis-directed SBRT: Results from a large international database;Radiotherapy and Oncology;2023-09

3. Neoadjuvant therapy for pancreatic cancer;Nature Reviews Clinical Oncology;2023-03-17

4. Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?;Life;2022-03-22